Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

Karin G. Schrenk, Andreas Hochhaus, Christian Spiegel et al.|Journal of Cancer Research and Clinical Oncology|2022

Cited by 7